CA9 and breast cancer: Overall, this study provides a detailed in vivo and metabolic evaluation of MMH-I in breast cancer, highlighting its potential as a CA IX-targeted therapeutic candidate and supporting further investigation of sulfonamide-based combination strategies against hypoxic tumors.